You are viewing the site in preview mode

Skip to main content

Table 1 Baseline characteristics and treatment details of rectal cancer patients treated with preoperative chemoradiation with capecitabine (n = 746)

From: Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study

Sex
 Male 477 (64%)
 Female 269 (35%)
Age (years) 64 (57–71)
T-stage
 2 33 (5%)
 3 539 (76%)
 4 134 (19%)
N-stage
 0 102 (14%)
 1 265 (37%)
 2 346 (49%)
M-stage
 0 659 (90%)
 1 74 (10%)
Primary rectal cancer 713 (96%)
Recurrent rectal cancer 33 (4%)
BMI (kg/m2) 25.8 (23.5–28.7)
Skeletal muscle mass
 Normal 306 (49%)
 Low 324 (51%)
Skeletal muscle density
 Normal 353 (56%)
 Low 278 (44%)
Capecitabine dosing scheme
 Weekdays only 300 (40%)
 Continuous 446 (60%)
Renal function
 eGFR < 60 ml/min/1.73 m2 51 (7%)
 eGFR ≥ 60 ml/min/1.73 m2 694 (93%)
Diarrhea
 No diarrhea 543 (73%)
 Grade 1 90 (12%)
 Grade 2 43 (6%)
 Grade 3 68 (9%)
 Grade 4 1 (0%)
 Grade 5 1 (0%)
  1. Percentages might not add up due to rounding
  2. BMI body mass index, eGFR estimated glomerular filtration rate
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us